Replies to post #554841 on $Stock*Shop*Charts*News*Option$

[Tuff-Stuff]

AbbVie's new hepatitis C drug gets boost

The price war over hepatitis C drugs continues, after Express Scripts (NASDAQ:ESRX) announced that it will only cover AbbVie's (NYSE:ABBV) newly approved Viekira Pak, which received clearance from the FDA on Friday.
The move will help the drug maker take market share away from Gilead Sciences (NASDAQ:GILD) and J&J (NYSE:JNJ), which make blockbuster hep C drugs, including Sovaldi, Harvoni and Olysio.
AbbVie's Viekira Pak will have a price of $83,319, although the agreement with Express Scripts involves a significant discount to that price.